Navigation Links
Old is gold– proved yet another tim

Chloroquine, an antimalarial drug was highly successful in combating the disease when launched in the 1950s.// It soon became useless because of resistance being developed by the malarial parasite.

Scientists have found a way to breathe new life into the drug. It has been found that combining the drug with another preparation, Primaquine, would restore the effect of the original drug.

Malaria is caused by the parasite Plasmodium falciparum and is associated with a significant mortality all over the world, especially in the developing countries.

Chloroquine - which is far cheaper than more modern malaria drugs - works by blocking the way the parasite breaks down human hemoglobin contained in red blood cells. If the haem molecules remain in an uncrystallised form, they are toxic to the parasite, thereby killing it.

On its own, primaquine has no effect on P. falciparum, but it is structurally similar to chloroquine. The right concentration and combination of Primaquine and Chloroquine has been found to be effective on chloroquine-resistant parasites.

It is believed that that the drug combination would work better as chloroquine would be prevented from leaking out by a parallel action of primaquine that acts to block the pores on the surface of the parasite's digestive system The finding promises hope and would be less expensive when compared to the existing treatment. This would also ensure that it is made available the poorest countries where need is greatest.

However, caution has to be taken because primaquine is not suitable for all patients, as it could trigger the break down of red blood cells in people with an enzyme deficiency. People would have to be tested for the same before the therapy can be instituted.
'"/>




Page: 1

Related medicine news :

1. Abortion Pill approved by FDA
2. Another injectable contraceptive Pill approved by FDA
3. Levothyroxine Thyroid Hormone Replacement, Approved for Hypothyroidism
4. New FDA Approved Drug To Treat Migraine
5. Lose Weight With New Wonder Slimming FDA approved Prescription Drug
6. New FDA Approved Drug NATRECOR For Heart Failure Patients
7. Voice may be improved by surgery
8. New oral antiviral treatment of cold sores approved
9. Survival rates in breast cancer patients improved with "Dose Dense Chemotherapy"
10. ICU Survival can be improved by Antibiotic use
11. Survival rate not improved by invasive procedures
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/21/2017)... ... ... Seamild, the largest manufacturer of oats in China, is now aiming at ... Oat is recognized globally as one of the healthiest cereals, XieQingkui, the founder of ... a move to sow the seed of good karma. Buddhism spirit featuring benevolence and ...
(Date:1/21/2017)... ... January 21, 2017 , ... In the United States, ... experience the freedom of recovery, they often feel shame for having struggled with an ... disorder (PTSD). In the workshop, “Rising Strong in Life After an Eating Disorder” -- ...
(Date:1/20/2017)... ... January 20, 2017 , ... Source Vitál Apothecary, a skin and body care ... announced the company had a successful visit to the 2017 ECRM Diet, Vitamin & ... that work in the nutritional, sports and health industries a chance to meet in ...
(Date:1/20/2017)... , ... January 20, 2017 , ... International Protein, a ... and bodybuilding supplements, announced it attended the January ECRM trade show in Hilton Head, ... nutritional scientist who was determined to create a line of products that would elevate ...
(Date:1/20/2017)... ... , ... “The Angel”: a heartwarming and earnest tale of faith and ... children. “The Angel” is the creation of published author, Marjorie Lund-Fontaine, a former professional ... writer. , When asked of her new book, Marjorie says, “‘The Angel’ was written ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)...  Abaxis, Inc. (NasdaqGS: ABAX ), a ... consumables for the medical and veterinary markets worldwide, has ... for the third quarter fiscal year 2017, ended December ... ET on Thursday, January 26, 2017.  The Company will ... 2017 after the market closes on Thursday, January 26, ...
(Date:1/19/2017)... 2017  Sensus Healthcare, Inc. (NASDAQ: ... the treatment of non-melanoma skin cancers and other ... therapy, today announced that it will report its ... on Thursday, February 2, 2017 after the market close. ... call with the investment community on Thursday, February 2, ...
(Date:1/19/2017)... 19, 2017 Shire plc (LSE: ... U.S. Food and Drug Administration (FDA) has acknowledged receipt ... Application (NDA) for SHP465, a long-acting, triple-bead, mixed amphetamine ... once-daily treatment for Attention-Deficit/Hyperactivity Disorder (ADHD). The FDA is ... 20, 2017, the designated Prescription Drug User Fee Act ...
Breaking Medicine Technology: